Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12425412 | 1.00 | HDAC1 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL15249213 | 1.00 | HDAC1 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL30316252 | 1.00 | HDAC1 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL29437386 | 1.00 | HDAC1 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL31106310 | 1.00 | HDAC1 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL22387840 | 1.00 | HDAC1 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL2301999 | 0.90 | GPR119 (0.47) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL15034386 | 0.87 | GPR119 (0.53) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL31459152 | 0.85 | GPR119 (0.52) | HDAC1GPR119HSD11B1PARP1CHRNB2 | |
| SCHEMBL30248832 | 0.85 | GPR119 (0.52) | HDAC1GPR119HSD11B1PARP1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | G1 THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| US-20210299130-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | G1 THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210213022-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | G1 THERAPEUTICS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10966984-B2 | Transient protection of normal cells during chemotherapy | G1 THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200345743-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | G1 THERAPEUTICS, INC. (US) | 2020-07-30 | — | — | US | disclosed |
| US-10696682-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | G1 THERAPEUTICS, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10189849-B2 | CDK inhibitors | G1 THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180201618-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201619-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180201617-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | US | disclosed |
| US-9957276-B2 | CDK inhibitors | GI Therapeutics, Inc. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170246171-A1 | Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors | G1 THERAPEUTICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170182043-A1 | Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors | G1 THERAPEUTICS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170100405-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | G1 THERAPEUTICS, INC. (US) | 2017-04-13 | — | — | US | disclosed |
| US-20170065597-A1 | Transient Protection of Normal Cells During Chemotherapy | G1 THERAPEUTICS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170057971-A1 | CDK Inhibitors | G1 THERAPEUTICS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189849-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | HDAC1 239/4885GPR119 3348/4885HSD11B1 1269/4885 |
| US-10696682-B2 | CDK inhibitors | CDK3, CDK9, CDK6 | HDAC1 239/4885GPR119 3348/4885HSD11B1 1269/4885 |
| US-10966984-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | HDAC1 246/4885GPR119 3817/4885HSD11B1 4129/4885 |
| US-20180201618-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | HDAC1 239/4885GPR119 3348/4885HSD11B1 1269/4885 |
| US-20200345743-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | HDAC1 301/4885GPR119 4239/4885HSD11B1 1841/4885 |
| US-20230381189-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | HDAC1 246/4885GPR119 3817/4885HSD11B1 4129/4885 |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | MKI67, DPYD, PCNA | HDAC1 452/4885GPR119 3709/4885HSD11B1 2408/4885 |
| US-20210299130-A1 | TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY | CDK6, CCNC, MCL1 | HDAC1 246/4885GPR119 3817/4885HSD11B1 4129/4885 |
| US-20200239486-A1 | PYRIMIDINE-BASED COMPOUNDS FOR THE TREATMENT OF CANCER | TYMS, TYMP, DPYD | HDAC1 2910/4885GPR119 3814/4885HSD11B1 3629/4885 |
| US-20170246171-A1 | Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 Inhibitors | RB1, CDK4, CDK6 | HDAC1 280/4885GPR119 3868/4885HSD11B1 2642/4885 |
| US-20170100405-A1 | HSPC-Sparing Treatments for RB-Positive Abnormal Cellular Proliferation | RB1, CDK4, CDKN1A | HDAC1 306/4885GPR119 2769/4885HSD11B1 4015/4885 |
| US-20180201619-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | HDAC1 239/4885GPR119 3348/4885HSD11B1 1269/4885 |
| US-10654831-B2 | Antiproliferative pyrimidine-based compounds | MKI67, TYMS, TYMP | HDAC1 1848/4885GPR119 3698/4885HSD11B1 3266/4885 |
| US-20210213022-A1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | RB1, CDK4, CDKN1A | HDAC1 306/4885GPR119 2769/4885HSD11B1 4015/4885 |
| US-20230241059-A1 | ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS | CDK4, RB1, BTK | HDAC1 872/4885GPR119 3843/4885HSD11B1 3679/4885 |
| US-20170065597-A1 | Transient Protection of Normal Cells During Chemotherapy | CDK6, CCNC, MCL1 | HDAC1 246/4885GPR119 3817/4885HSD11B1 4129/4885 |
| US-20170182043-A1 | Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors | CDK4, RB1, CDK6 | HDAC1 304/4885GPR119 3749/4885HSD11B1 3496/4885 |
| US-20170057971-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | HDAC1 239/4885GPR119 3348/4885HSD11B1 1269/4885 |
| US-20180201617-A1 | CDK Inhibitors | CDK3, CDK9, CDK6 | HDAC1 239/4885GPR119 3348/4885HSD11B1 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.